GlassScriptPhysician profile
Dusit Adstamongkonkul
NPI 1619382645
$9,182.73
in general payments reported to CMS, 2019-2025
62 companies · $2,626 in 2025
The $2,626 reported for 2025 was more than what 81% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $617 · 2020: $1,024 · 2021: $727 · 2022: $861 · 2023: $1,105 · 2024: $2,224 · 2025: $2,626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,798 · Travel and Lodging: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,798.20 |
| Travel and Lodging | $155.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $2,071.13 | 2019-2023 | Qelbree |
| Ucb, INC. | $987.91 | 2019-2025 | Fintepla, Briviact, Nayzilam |
| Abbvie INC. | $618.83 | 2022-2025 | Ubrelvy, Duopa, Qulipta |
| Neuropace, INC. | $542.61 | 2024 | |
| Jazz Pharmaceuticals INC. | $460.12 | 2022-2025 | |
| Neurelis, INC. | $327.22 | 2021-2025 | Valtoco |
| Neurocrine Biosciences, INC. | $288.14 | 2023-2025 | Ingrezza, Ongentys |
| Eisai INC. | $281.59 | 2021-2025 | |
| Emd Serono, INC. | $275.15 | 2023-2025 | Mavenclad |
| Celgene Corporation | $233.04 | 2024-2025 | Zeposia |
| Octapharma USA, INC. | $215.10 | 2024-2025 | Panzyga |
| Livanova USA, INC. | $203.81 | 2022-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Biogen, INC. | $194.81 | 2020-2025 | Vumerity, Tysabri, Leqembi |
| Lilly USA, LLC | $189.43 | 2024-2025 | Kisunla, Amyvid, Emgality |
| Alexion Pharmaceuticals, INC. | $165.32 | 2022-2025 | Ultomiris, Soliris |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dusit Adstamongkonkul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.